CurrentAnesthesia — Sepsis & infection

Association of Vitamin C, Thiamine, and Hydrocortisone Infusion With Long-term Cognitive, Psychological, and Functional Outcomes in Sepsis Survivors: A Secondary Analysis of the Vitamin C, Thiamine, and Steroids in Sepsis Randomized Clinical Trial

2026-10-28T04:44:26.953Z

Secondary analysis · JAMA Netw Open, 2023. Long-term cognitive, psychological and functional outcomes, 6 months — Intervention vs Control: aOR 0.49 (95% CI 0.26-0.89); immediate memory scores (lower)

Defining Posttraumatic Sepsis for Population-Level Research

2026-10-28T04:44:26.953Z

Cohort study · JAMA Netw Open, 2023. Chronic critical illness and in-hospital mortality — Automated clinical criteria: adjusted RR of chronic critical illness 9.9 (95% CI 8.0-12.3)

Early Restrictive or Liberal Fluid Management for Sepsis-Induced Hypotension

2026-10-28T04:42:32.209Z

Randomised controlled trial · N Engl J Med, 2023. All-cause mortality before discharge home, day 90: Restrictive fluid 109 (14.0%) · Liberal fluid 116 (14.9%)

Hydrocortisone in Severe Community-Acquired Pneumonia

2026-10-28T04:42:32.209Z

Randomised controlled trial · N Engl J Med, 2023. Death, day 28: Hydrocortisone 25 (6.2% (95% CI 3.9 to 8.6)) · Placebo 47 (11.9% (95% CI 8.7 to 15.1))

Contamination of Blood Cultures From Arterial Catheters and Peripheral Venipuncture in Critically Ill Patients: A Prospective Multicenter Diagnostic Study

2026-10-28T04:40:50.491Z

Diagnostic or prognostic study · Chest, 2023. Contamination proportion: Arterial catheter 2 (0.3%) · Venipuncture 4 (0.7%)

High-Dose IV Hydroxocobalamin (Vitamin B12) in Septic Shock: A Double-Blind, Allocation-Concealed, Placebo-Controlled Single-Center Pilot Randomized Controlled Trial (The Intravenous Hydroxocobalamin in Septic Shock Trial)

2026-10-28T04:40:50.491Z

Randomised controlled trial · Chest, 2022. Study feasibility: Enrollment rate (20 patients over 19 months), patients per month 1.05

Is Left Ventricular Systolic Dysfunction Associated With Increased Mortality Among Patients With Sepsis and Septic Shock?

2026-10-28T04:40:50.491Z

Cohort study · Chest, 2023. In-hospital mortality: LVEF < 25% 51.1% · 25% ≤ LVEF < 40% 34.8% · 40% ≤ LVEF < 55% 26.6% · 55% ≤ LVEF < 70% 26.2% · LVEF ≥ 70% 41.9%

Monocyte Distribution Width as a Diagnostic Marker for Infection: A Systematic Review and Meta-analysis

2026-10-28T04:40:50.491Z

Meta-analysis · Chest, 2023. Diagnostic performance of MDW for sepsis (19 studies) and COVID-19 (six studies), pooled: Sepsis: pooled AUC 0.74 to 0.94

Clinical effectiveness of tigecycline in combination therapy against nosocomial pneumonia caused by CR-GNB in intensive care units: a retrospective multi-centre observational study

2026-10-28T04:36:50.728Z

Cohort study · J Intensive Care, 2023. All-cause mortality, day 28: Tigecycline 27.7% · Without tigecycline 36.0%

Mortality analysis among sepsis patients in and out of intensive care units using the Japanese nationwide medical claims database: a study by the Japan Sepsis Alliance study group

2026-10-28T04:36:50.728Z

Cohort study · J Intensive Care, 2023. In-hospital mortality (propensity score matched): Non-ICU 29.2% · ICU 25.8%

Sepsis-related coagulopathy treatment based on the disseminated intravascular coagulation diagnostic criteria: a post-hoc analysis of a prospective multicenter observational study

2026-10-28T04:36:50.728Z

Secondary analysis · J Intensive Care, 2023. Organ dysfunction, in-hospital mortality and anticoagulant therapy benefit by DIC score and PT-INR: Organ dysfunction and in-hospital mortality worsened with higher PT-INR (range < 1.5), more pronounced with higher DIC scores

Alactic base excess is an independent predictor of death in sepsis: A propensity score analysis

2026-10-28T04:33:02.462Z

Cohort study · J Crit Care, 2023. Mortality — Negative ABE vs Neutral ABE: adjusted HR 1.43 (95% CI 1.02-2.01); Cox regression with inverse probability weighting (IPWT)

Assessing a standardized decision-making algorithm for blood culture collection in the intensive care unit

2026-10-28T04:33:02.462Z

Cohort study · J Crit Care, 2023. Inappropriate blood cultures: Patients with ≥1 blood culture drawn 167

The clinical and paraclinical effectiveness of four-hour infusion vs. half-hour infusion of high-dose ampicillin-sulbactam in treatment of critically ill patients with sepsis or septic shock: An assessor-blinded randomized clinical trial

2026-10-28T04:33:02.462Z

Randomised controlled trial · J Crit Care, 2022.

Clinical significance of thrombocytopenia in patients with septic shock: An observational retrospective study

2026-10-28T04:33:02.462Z

Cohort study · J Crit Care, 2023. ICU-acquired bleeding events: Severe 20.3% · Mild 15.3% · Relative 14.4% · Non-thrombocytopenic 3.6%

Clostridioides difficile infection in mechanically ventilated critically ill patients: A nested cohort study

2026-10-28T04:33:02.462Z

Cohort study · J Crit Care, 2023. CDI incidence and prevalence: Patients diagnosed with CDI 86

Definitions, rates and associated mortality of ICU-acquired pneumonia: A multicenter cohort study

2026-10-28T04:33:02.462Z

Randomised controlled trial · J Crit Care, 2023. Frequency of ICU-acquired pneumonia: VAP 21.6% · CPIS 24.9% · ACCP 25.0% · ISF 24.4% · REDOXS 17.6% · CDC 7.8% · Invasively microbiologically confirmed 1.9%

Diagnosing acute kidney injury ahead of time in critically ill septic patients using kinetic estimated glomerular filtration rate

2026-10-28T04:33:02.462Z

Cohort study · J Crit Care, 2023. AKI diagnosis: KeGFR 1706 (68.5%); sensitivity 93.2%; specificity 73.0%; accuracy 85.7%; kappa (disease stages) 0.77 · KDIGO 1560 (62.0%)

Diagnosing sepsis in the ICU: Comparison of a gene expression signature to pre-existing biomarkers

2026-10-28T04:33:02.462Z

Diagnostic or prognostic study · J Crit Care, 2023. Discrimination of blood culture positive sepsis vs aseptic inflammation: Gene signature: AUC 0.97 (95% CI, 0.95-0.99) · C-reactive protein: AUC 0.72 (95% CI, 0.57-0.87) · NT-Pro B-type Natriuretic Peptide: AUC 0.84 (95% CI, 0.73-0.96) · Septicyte™ LAB: AUC 0.8 (95% CI, 0.68-0.93) · Procalcitonin: AUC 0.96 (95% CI, 0.9-1)

Incidence, risk factors and pre-emptive screening for COVID-19 associated pulmonary aspergillosis in an era of immunomodulant therapy

2026-10-28T04:33:02.462Z

Cohort study · J Crit Care, 2023. CAPA incidence: CAPA 295 (14.9%)

Refractory septic shock and alternative wordings: A systematic review of literature

2026-10-28T04:33:02.462Z

Meta-analysis · J Crit Care, 2023. Definitions of terms: Catecholamine resistance generally defined as decreased vascular responsiveness to catecholamine independently of the norepinephrine dose

The effect of duration of antimicrobial treatment for bacteremia in critically ill patients on in-hospital mortality – Retrospective double center analysis

2026-10-28T04:33:02.462Z

Cohort study · J Crit Care, 2023. Time from start of antimicrobial treatment to in-hospital death or discharge (in-hospital survival): No differences in in-hospital survival between shorter and longer treatment

Usefulness of differential time to positivity between catheter and peripheral blood cultures for diagnosing catheter-related bloodstream infection: Data analysis from routine clinical practice in the intensive care unit

2026-10-28T04:33:02.462Z

Diagnostic or prognostic study · J Crit Care, 2023. Diagnostic accuracy for CRBSI: DTP ≥120 min: sensitivity 41%; specificity 74% · DTP (all values): AUC 0.60 [95%CI: 0.48-0.72] · Ratio 0.80: sensitivity 46%; specificity 79%

Association of systolic, diastolic, mean, and pulse pressure with morbidity and mortality in septic ICU patients: a nationwide observational study

2026-10-28T04:30:32.433Z

Cohort study · Ann Intensive Care, 2023. ICU mortality: Lower values of all BP components associated with higher risk of ICU mortality

Clinical significance of human metapneumovirus detection in critically ill adults with lower respiratory tract infections

2026-10-28T04:30:32.433Z

Meta-analysis · Ann Intensive Care, 2023. Rate of hMPV LRTIs (meta-analysis): hMPV 45% (95% CI 31-60%)

Effects of 12 mg vs. 6 mg dexamethasone on thromboembolism and bleeding in patients with critical COVID-19 - a post hoc analysis of the randomized, blinded COVID STEROID 2 trial

2026-10-28T04:30:32.433Z

Secondary analysis · Ann Intensive Care, 2023. Composite of death or thromboembolism during intensive care, during intensive care: 12 mg 53 (29%) · 6 mg 53 (30%)

Efficacy of carbapenem vs non carbapenem β-lactam therapy as empiric antimicrobial therapy in patients with extended-spectrum β-lactamase-producing Enterobacterales urinary septic shock: a propensity-weighted multicenter cohort study

2026-10-28T04:30:32.433Z

Cohort study · Ann Intensive Care, 2023. Mortality, Day 30: Carbapenem 10 (15%) · Non carbapenem 6 (7%)

ICU patients with infectious complications after abdominopelvic surgery: Is thoracic CT in addition to abdominal CT helpful?

2026-10-28T04:30:32.433Z

Diagnostic or prognostic study · Ann Intensive Care, 2023. Infectious focus: Thoracoabdominal CT: diagnostic efficacy 3.5% (95%-CI: 0.5-6.5%); therapeutic efficacy 0.7% (95%-CI: 0-2.1%)

Impact of a strategy based on unique blood culture sampling on contamination rate and detection of bloodstream infections in critically ill patients

2026-10-28T04:30:32.433Z

Research article · Ann Intensive Care, 2023. BC contamination per patient: MS 11.2% · UBC 3.8%

Impact of renal replacement therapy strategy on beta-lactam plasma concentrations: the BETAKIKI study—an ancillary study of a randomized controlled trial

2026-10-28T04:30:32.433Z

Secondary analysis · Ann Intensive Care, 2023. Proportion of patients with sufficient beta-lactam trough plasma concentration (>4 times the MIC): Early 79.2% · Delayed 81.4%

Intravenously administered interleukin-7 to reverse lymphopenia in patients with septic shock: a double-blind, randomized, placebo-controlled trial

2026-10-28T04:30:32.433Z

Randomised controlled trial · Ann Intensive Care, 2023. Absolute lymphocyte counts: Two-threefold increase in absolute lymphocyte counts (incl. CD4+ and CD8+ T cells) with CYT107 vs placebo, maintained throughout follow-up, reversing severe lymphopenia all p < 0.05

Role of nebulized colistin as a substitutive strategy against nosocomial pneumonia caused by CR-GNB in intensive care units: a retrospective cohort study

2026-10-28T04:30:32.433Z

Cohort study · Ann Intensive Care, 2023. Clinical failure rate, PS-matched cohort, Day 14: Nebulized colistin 27.0 % · No nebulized colistin 42.6%

The prevalence of sepsis-induced coagulopathy in patients with sepsis – a secondary analysis of two German multicenter randomized controlled trials

2026-10-28T04:30:32.433Z

Secondary analysis · Ann Intensive Care, 2023. SIC prevalence: HYPRESS 22.1% (95% CI 17.5-27.5%) · SISPCT 24.2% (95% CI 21.6-26.9%)

Trends in clinical characteristics and outcomes of all critically ill COVID-19 adult patients hospitalized in France between March 2020 and June 2021: a national database study

2026-10-28T04:30:32.433Z

Cohort study · Ann Intensive Care, 2023. In-hospital mortality: Surge 1 24%

Catastrophic COVID-19 Delta Variant Surge in French West Indies: Report of an ICU Triage Policy*

2026-10-28T04:21:38.918Z

Cohort study · Crit Care Med, 2022. 90-day mortality, 90 days: Green 24% · Orange 37% · Red 78%

Comparison of the Diagnostic Accuracies of Monocyte Distribution Width, Procalcitonin, and C-Reactive Protein for Sepsis: A Systematic Review and Meta-Analysis

2026-10-28T04:21:38.918Z

Meta-analysis · Crit Care Med, 2023. Pooled diagnostic accuracy of MDW: MDW: sensitivity 84% (95% CI 79-88%); specificity 68% (95% CI 60-75%); diagnostic OR 11.11 (95% CI 7.36-16.77); AUC (SROC) 0.85 (95% CI 0.81-0.89)

COVID-19 and the Genetics of Inflammation

2026-10-28T04:21:38.918Z

Research article · Crit Care Med, 2023. Genetic predispositions to severe COVID-19: Genetic variants affecting inflammatory responses may increase susceptibility to severe COVID-19

Obesity Paradox and Functional Outcomes in Sepsis: A Multicenter Prospective Study

2026-10-28T04:21:38.918Z

Cohort study · Crit Care Med, 2023. Hospital mortality: Obese 25.3% · Nonobese 36.7%

Outcomes and Adverse Effects of Baricitinib Versus Tocilizumab in the Management of Severe COVID-19*

2026-10-28T04:21:38.918Z

Cohort study · Crit Care Med, 2022. In-hospital mortality: No difference in mortality between the two groups

Perceived Hospital Stress, Severe Acute Respiratory Syndrome Coronavirus 2 Activity, and Care Process Temporal Variance During the COVID-19 Pandemic*

2026-10-28T04:21:38.918Z

Cohort study · Crit Care Med, 2023. Perceived overall hospital stress, mean % of hospitals per week (SD 36%) 43%

Risk Factors for Major Cardiovascular Events in Adult Sepsis Survivors: A Population-Based Cohort Study*

2026-10-28T04:21:38.918Z

Cohort study · Crit Care Med, 2023. Factors associated with major cardiovascular events (multivariable-adjusted), median follow-up 3 years: Major cardiovascular event incidence 10.4%

Complement activation in severely ill patients with sepsis: no relationship with inflammation and disease severity

2026-10-28T04:14:48.087Z

Secondary analysis · Crit Care, 2023. Complement factors (C3, C3a, C3c, C5, C5a, soluble terminal complement complex) in plasma within 24 h of sepsis diagnosis, within 24 h after sepsis diagnosis: Profound activation of the complement system vs healthy controls all P < 0.01

COVID-19 bacteremic co-infection is a major risk factor for mortality, ICU admission, and mechanical ventilation

2026-10-28T04:14:48.087Z

Cohort study · Crit Care, 2023. In-hospital mortality, ICU admission, mechanical ventilation with bacterial co-infection (aOR, by cohort) — Bacterial co-infection (UAB): aOR (in-hospital mortality) 3.07 (95% CI 2.42-5.46); p < 0.001

Early adjunctive methylene blue in patients with septic shock: a randomized controlled trial

2026-10-28T04:14:48.087Z

Randomised controlled trial · Crit Care, 2023. Time to vasopressor discontinuation, 28 days: MB 69 (IQR 59-83) h · Placebo 94 (IQR 74-141) h

Efficacy and safety of baricitinib in hospitalized adults with severe or critical COVID-19 (Bari-SolidAct): a randomised, double-blind, placebo-controlled phase 3 trial

2026-10-28T04:14:48.087Z

Randomised controlled trial · Crit Care, 2023. All-cause mortality, day 60: Baricitinib 21 (15.1%) · Placebo 21 (15.4%)

National incidence and mortality of hospitalized sepsis in China

2026-10-28T04:14:48.087Z

Cohort study · Crit Care, 2023. Annual standardized incidence of hospitalized sepsis (cases per 100,000): 2017 328.25 (95% CI 315.41-341.09)

Severe community-acquired Streptococcus pneumoniae bacterial meningitis: clinical and prognostic picture from the intensive care unit

2026-10-28T04:14:48.087Z

Cohort study · Crit Care, 2023. Clinical response, 72 h: Clinical response achieved 65.8%

The outcome of IV vitamin C therapy in patients with sepsis or septic shock: a meta-analysis of randomized controlled trials

2026-10-28T04:14:48.087Z

Meta-analysis · Crit Care, 2023. Delta SOFA score, 72-96 h — IVVC vs Control: MD - 0.62 (95% CI - 1.00 to - 0.25); p = 0.001

Epidemiology, clinical presentation, and outcomes of 620 patients with eosinophilia in the intensive care unit

2026-10-28T04:13:06.971Z

Cohort study · Intensive Care Med, 2023. Prevalence and timing of eosinophilia in ICU: ICU-Eo1 40% · ICU-Eo2 56%

Epidemiology and outcomes of hospital-acquired bloodstream infections in intensive care unit patients: the EUROBACT-2 international cohort study

2026-10-28T04:13:06.971Z

Cohort study · Intensive Care Med, 2023. Epidemiology and outcomes of HA-BSI: ICU-acquired HA-BSI 78%